Evidence map›Paper›PMID 32943093›Full record

ArticleTrials2020

Patient and healthcare professional experiences of the Salford Lung Studies: qualitative insights for future effectiveness trials.

Kim Gemzoe, Rebecca Crawford, Ann Caress, Sheila McCorkindale, Rebecca Conroy, Susan Collier, Lynda Doward, Renu M Vekaria, Sally Worsley, David A Leather and 1 more

Abstract read
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kim GemzoeReal World Study Delivery, Value Evidence and Outcomes, GlaxoSmithKline plc., Research & Development Ltd., Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex, UB11 1BT, UK. kim.x.gemzoe@gsk.com.ORCID http://orcid.org/0000-0002-4651-327X
Rebecca CrawfordRTI Health Solutions, Manchester, M20 2LS, UK.
Ann CaressSchool of Human and Health Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK.
Sheila McCorkindaleNIHR Clinical Research Network Greater Manchester, Manchester, M13 9NQ, UK.
Rebecca ConroyRTI Health Solutions, Manchester, M20 2LS, UK.
Susan CollierUK Medical, GlaxoSmithKline plc, Uxbridge, UB11 1BT, UK.
Lynda DowardRTI Health Solutions, Manchester, M20 2LS, UK.
Renu M VekariaRTI Health Solutions, Manchester, M20 2LS, UK.
Sally WorsleyReal World Study Delivery, Value Evidence and Outcomes, GlaxoSmithKline plc., Research & Development Ltd., Stevenage, SG1 2NY, UK.
David A LeatherGlobal Respiratory Franchise, GlaxoSmithKline plc., Brentford, TW8 9GS, UK.
Elaine IrvingReal World Study Delivery, Value Evidence and Outcomes, GlaxoSmithKline plc., Research & Development Ltd., Stevenage, SG1 2NY, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRandomized controlled trials (RCTs) conducted in the routine care setting provide the opportunity to better understand the effectiveness of new medicines but can present recruitment difficulties. An improved understanding of the challenges/opportunities for patient and healthcare professional (HCP) engagement in clinical research is needed to enhance participation and trial experience. In this study, we explored patient and HCP drivers for, and experiences of, participation in the Salford Lung Studies (SLS), and their views on future trial participation and the overall value of such trials.

methodsThis was a qualitative study set in Salford, UK, comprising patient telephone interviews (N = 10) and HCP advisory boards (one with general practitioners [GPs], one with practice managers [PMs]); all individuals had participated in the SLS. Semi-structured telephone interviews were recorded, transcribed and analysed thematically. Advisory board meetings were analysed based on transcriptions of audio recordings and field notes.

resultsFor patients, key positive aspects of the SLS were the ease/convenience of study assessments and excellent relationships with study nurses. GPs and PMs considered the SLS to be well-organized and highlighted the value of research nurse support; they also described minor challenges relating to trial systems, initial financial strain on practices and staff turnover. All participants indicated that they were very likely to participate in future trials, citing a design closely aligned with routine care practice as essential. Several strategies to encourage trial participation were suggested, such as clearly communicating benefits to patients and ensuring flexible study assessments.

conclusionsPatients and HCPs had positive experiences of the SLS. The study design, closely aligned with routine care, was considered important to their high likelihood of participating in future trials. The experiences of patients and HCPs in the SLS provide valuable insights that will help inform future best practice in the design and conduct of future real-world effectiveness RCTs in primary care. The detailed first-hand experiences of HCPs will be of significant value to others considering engaging in clinical research and participating in effectiveness RCTs.

Indexed as

Health PersonnelPrimary Health CareDelivery of Health CareHumansLungQualitative ResearchEffectiveness trialSalford Lung Studies (SLS)Trial experience

Identifiers

PMID32943093
PMCPMC7499906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.